Psyence BioMed backs Trump ibogaine initiative

Psyence BioMed supports U.S. ibogaine development

Psyence BioMed Ltd. announced its readiness to aid in the development of ibogaine as a medical treatment following President Donald Trump's recent statement highlighting the substance's potential. The announcement coincides with company executives meeting stakeholders in Texas to explore ibogaine clinical development opportunities, according to a press release.

Trump's ibogaine announcement

President Trump revealed that the University of Miami has provided the U.S. Federal Government with its 1994 ibogaine Investigational New Drug application. This move is seen as a potential catalyst for advancing ibogaine's development as a therapeutic option. Trump also highlighted progress since his April Executive Order, which includes research funding, agency collaboration, FDA guidance, and efforts to enhance Right to Try access for veterans.

Psyence BioMed's strategic positioning

Jody Aufrichtig, CEO of Psyence BioMed, emphasized the company's alignment with the U.S. government's call for serious entities to advance ibogaine research. Alongside CFO Warwick Corden-Lloyd, Aufrichtig is in Texas to discuss the regulatory and policy landscape with U.S. stakeholders. Psyence BioMed holds an interest in PsyLabs, a pharmaceutical manufacturing operation capable of producing GMP-compliant ibogaine hydrochloride, providing the company with manufacturing capabilities and inventory.

Regulatory context

Despite these developments, ibogaine remains a controlled substance in the United States. Psyence BioMed has not yet conducted clinical trials for its proposed ibogaine products, and the efficacy of these products has not been confirmed through authorized clinical research.

Why it matters

The alignment of Psyence BioMed with federal initiatives underscores the growing interest in ibogaine as a potential treatment for various conditions, including opioid use disorder. The company's involvement could accelerate research and development efforts, potentially leading to new therapeutic options for patients.

Psyence BioMed's engagement with the U.S. ibogaine ecosystem highlights the increasing collaboration between private enterprises and government bodies in the field of psychedelic research.